Resistomycin as a DNA-targeted topoisomerase II inhibitor: Computational and mechanistic insights into its anticancer potential
Journal of Chemical Research · مجلد 49 (5)
Resistomycin, a microbial secondary metabolite, exhibits promising anticancer potential, yet its mechanism of action remains poorly understood. Here, we combined computational and biological assays to investigate its activity against Topoisomerase II (Topo II). Molecular docking predicted strong binding within the Topo II–DNA complex (–20.76 kcal/mol), while 200 ns molecular dynamics simulations confirmed a stable intercalation mode. Energy decomposition revealed van der Waals interactions as the dominant stabilizing force, with persistent hydrophobic and π-stacking contacts to DNA bases. This non-polar binding profile distinguishes resistomycin from classical Topo II inhibitors. In line with these predictions, resistomycin inhibited Topo II activity with an IC₅₀ of 21.48 nM, surpassing doxorubicin (30.16 nM). Cell-based assays further showed selective cytotoxicity across multiple cancer cell lines (IC₅₀ = 45.68–72.30 µM), while mechanistic studies in HCT-116 cells demonstrated dose-dependent apoptosis and G2/M cell cycle arrest. Collectively, these findings identify resistomycin as a potent DNA-intercalating Topo II inhibitor with a unique binding signature, supporting its potential as a scaffold for developing next-generation anticancer agents.
